Clinical Trial: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Study Status: Completed
Recruit Status: RECRUITING
Condition: Parkinson Disease Psychosis
Study Type: INTERVENTIONAL
Official Title: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Brief Summary:
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease.Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between.Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine…
Read more